Nomegestrol Acetate / Estradiol — Competitive Intelligence Brief

Nomegestrol Acetate / Estradiol (Nomegestrol Acetate / Estradiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Gynecology.

marketed Combined oral contraceptive Progesterone receptor, Estrogen receptor Contraception / Gynecology Small molecule

Target snapshot

Nomegestrol Acetate / Estradiol (Nomegestrol Acetate / Estradiol) — University of Palermo. Nomegestrol acetate and estradiol work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nomegestrol Acetate / Estradiol TARGET	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
Ortho Tri-Cyclen LO	Ortho Tri-Cyclen LO	Bristol-Myers Squibb	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Intermittent OC (EE/DROS)	Intermittent OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Phase 3 NOMAC-E2 "Batch A"	Phase 3 NOMAC-E2 "Batch A"	Organon and Co	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
YAZ®	YAZ®	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class